V
Vandana Solanki
Researcher at Central University of Rajasthan
Publications - 18
Citations - 346
Vandana Solanki is an academic researcher from Central University of Rajasthan. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 9 publications receiving 202 citations.
Papers
More filters
Journal ArticleDOI
Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii.
TL;DR: Using subtractive proteomics, it is identified promiscuous antigenic membrane proteins that contain the virulence factors, resistance factors and essentiality factor for this pathogenic bacteria A. baumannii.
Journal ArticleDOI
Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against Pseudomonas aeruginosa.
TL;DR: A chimeric vaccine againstMultidrug-resistant Pseudomonas aeruginosa is designed with the help of comparative proteomics and reverse vaccinology approaches and Immunogenic peptides were used to design a multi-epitope vaccine construct.
Journal ArticleDOI
Polyvinylpyrrolidone-Capped Silver Nanoparticle Inhibits Infection of Carbapenem-Resistant Strain of Acinetobacter baumannii in the Human Pulmonary Epithelial Cell.
TL;DR: PVP-AgNPs can be developed as a substitute for carbapenem to control the infection caused by carbapENem-resistant A. baumannii.
Journal ArticleDOI
Host-bacteria interaction and adhesin study for development of therapeutics.
TL;DR: The present study will help researchers to have a detailed understanding of different interacting bacterial adhesins and henceforth, develop new therapies, adhesin specific antibodies and vaccines, which can effectively control pathogenicity of the pathogens.
Journal ArticleDOI
Subtractive Proteomics and Reverse Vaccinology Strategies for Designing a Multiepitope Vaccine Targeting Membrane Proteins of Klebsiella pneumoniae
TL;DR: Analysis showed that VK2 multi-epitope vaccine could be a suitable target to control the K. pneumoniae infections.